Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

• the present invention relates to use of SHP2 inhibitors for the treatment of insulin resistance.
• SHP2 is a ubiquitous tyrosine phosphatase that regulates major signalling pathways (e.g. MAPK, PI3K) in response to many growth factors, thereby having key functions during development, so that its dysregulation has been linked to developmental disorders as well as cancers ( Tar an , M., de Rocca Serra, A., Valet, P., Edouard, T., and Yart, A. (2015). SHP2 sails from physiology to pathology. European journal of medical genetics 58, 509-525.).
• major signalling pathways e.g. MAPK, PI3K
• SHP2 also plays major roles in metabolism regulation, as evidenced by the severe phenotype of its targeted invalidation in various tissues and organs, however the global metabolic role of SHP2, and the contribution of its deregulation to metabolic diseases, have never been ascertained ( Tar an , M., de Rocca Serra, A., Valet, P., Edouard, T., and Yart, A. (2015). SHP2 sails from physiology to pathology. European journal of medical genetics 58, 509-525.).
• SHP2 inhibitors have been described in the prior art (e.g. W02010121212 and WO2015003094) but their use in the treatment of insulin resistance has never been described.
• mice with a neuron-specific, conditional Shp2 deletion developed obesity and diabetes and the associated pathophysiological complications that resemble those encountered in humans, including hyperglycemia, hyperinsulinemia, hyperleptinemia, insulin and leptin resistance, vasculitis, diabetic nephropathy, urinary bladder infections, prostatitis, gastric paresis, and impaired spermatogenesis ( Krajewska Ml, Banares S, Zhang EE, Huang X, Scadeng M, Jhala US, Feng GS, Krajewski S Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase. Am J Pathol. 2008 May;172(5):1312-24.).
• the present invention relates to use of SHP2 inhibitors for the treatment of insulin resistance.
• the present invention is defined by the claims.
• the first object of the present invention relates to a method of treating insulin resistance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a SHP2 inhibitor.
• the term "subject” refers to a human or another mammal (e.g., primate, dog, cat, goat, horse, pig, mouse, rat, rabbit, and the like), that can be afflicted with lupus.
• the subject is a human being.
• the subject is often referred to as an "individual”.
• the term “individual” does not denote a particular age, and thus encompasses children, teenagers, and adults.
• insulin resistance has its common meaning in the art. Insulin resistance is a physiological condition where the natural hormone insulin becomes less effective at lowering blood sugars. The resulting increase in blood glucose may raise levels outside the normal range and cause adverse health effects such as metabolic syndrome, dyslipidemia and subsequently type 2 diabetes mellitus. The method of the present invention is thus particularly suitable for the treatment of type 2 diabetes.
• type 2 diabetes or“non insulin dependent diabetes mellitus (NIDDM)” has its general meaning in the art. Type 2 diabetes often occurs when levels of insulin are normal or even elevated and appears to result from the inability of tissues to respond appropriately to insulin. Most of the type 2 diabetics are obese.
• the subject suffers from obesity.
• obesity refers to a condition characterized by an excess of body fat.
• the operational definition of obesity is based on the Body Mass Index (BMI), which is calculated as body weight per height in meter squared (kg/m 2 ).
• BMI Body Mass Index
• Obesity refers to a condition whereby an otherwise healthy subject has a BMI greater than or equal to 30 kg/m 2 , or a condition whereby a subject with at least one co-morbidity has a BMI greater than or equal to 27 kg/m 2 .
• An “obese subject” is an otherwise healthy subject with a BMI greater than or equal to 30 kg/m 2 or a subject with at least one co-morbidity with a BMI greater than or equal 27 kg/m 2 .
• a “subject at risk of obesity” is an otherwise healthy subject with a BMI of 25 kg/m 2 to less than 30 kg/m 2 or a subject with at least one co-morbidity with a BMI of 25 kg/m 2 to less than 27 kg/m 2 .
• the increased risks associated with obesity may occur at a lower BMI in people of Asian descent.
• “obesity” refers to a condition whereby a subject with at least one obesity-induced or obesity-related co-morbidity that requires weight reduction or that would be improved by weight reduction, has a BMI greater than or equal to 25 kg/m 2 .
• An “obese subject” in these countries refers to a subject with at least one obesity-induced or obesity- related co-morbidity that requires weight reduction or that would be improved by weight reduction, with a BMI greater than or equal to 25 kg/m 2 .
• a "subject at risk of obesity” is a person with a BMI of greater than 23 kg/m 2 to less than 25 kg/m 2 .
• treatment refers to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of subject at risk of contracting the disease or suspected to have contracted the disease as well as subjects who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
• the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
• therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
• a therapeutic regimen may include an induction regimen and a maintenance regimen.
• the phrase “induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
• the general goal of an induction regimen is to provide a high level of drug to a subject during the initial period of a treatment regimen.
• An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
• maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years).
• a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
• the method of the present invention is particularly suitable for improving blood glucose control, enhancing insulin signalling in skeletal muscle and adipose tissue, reducing lipotoxicity in skeletal muscle and adipose tissue, increasing lipid oxidative capacity in skeletal muscle and adipose tissue, or maintaining long-term insulin sensitivity in the subject.
• SHP2 has its general meaning in the art and refers to the protein encoded by the PTPN 11 gene.
• SHP2 is a non-receptor protein tyrosine phosphatase (PTP) with two Src homology- 2 (SH2) domains (N-SH2, C-SH2) (Alonso et. a , 2004; Neel et a , 2003).
• PTP non-receptor protein tyrosine phosphatase
• N-SH2, C-SH2 Src homology- 2 domains
• SHP2 is also known as Homo sapiens protein tyrosine phosphatase, non-receptor type 11 (PTPN 11).
• a“SHP2 inhibitor” refers to any compound natural or not which is capable of inhibiting the activity of SHP2, in particular SHP2 phosphatase activity.
• SHP2 inhibitors are well known in the art. The term encompasses any SHP2 inhibitor that is currently known in the art or that will be identified in the future. The term also encompasses inhibitor of expression.
• the SHP2 inhibitor is selective over the other phosphatases including SHP1.
• “selective” it is meant that the inhibition of the selected compound is at least 10-fold, preferably 25-fold, more preferably 100-fold, and still preferably 300-fold higher than the inhibition of the other phosphatases. Typical assays are also described in W02010121212 and W02015003094.
• the SHP2 inhibitor is a small organic molecule.
• Non-limiting examples of SHP2 inhibitors include NSC-87877 (also known as 8- Hydroxy-7-[(6-sulfo-2-naphthyl)azo]-5-quinolinesulfonic acid), estradiol phosphate, estramustine phosphate, PHPS1, NSC-117199, SP1-112, SPl-112Me (and see Chen, L. et a , 2006 and Chen, L. et a , 2010), tautomycetin analogs (e.g., see Liu, S. et a , 2011), phenylhydrazonopyrazolone sulfate and compounds described in Hellmuth, K. et a , 2008, compounds described in United States Patent Application Publication No. 20120034186 (U.S. Ser. No. 13/274,699) and compounds described in Yu, Z. H. et al. 2011.
• the SHP2 inhibitor for use according to the present invention is selected from compounds described in W02010121212, W02015003094, W02017100279, and W02007117699.
• the SHP2 inhibitor for use according to the present invention is 4,4'-(4'-Carboxy)-4- nonyloxy-[l,l '-biphenyl]-3,5-diyl)dibutanoic acid.
• the SHP2 inhibitor for use according to the present invention is SHP099: 6-(4-amino-4-methylpiperidin-l-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (Garcia Fortanet J, Chen CH, Chen YN, Chen Z, Deng Z, Firestone B, Fekkes P, Fodor M, Fortin PD, Fridrich C, Grunenfelder D, Ho S, Kang ZB, Karki R, Kato M, Keen N, LaBonte LR, Larrow J, Lenoir F, Liu G, Liu S, Lombardo F, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Ramsey T, Sellers WR, Shultz MD, Stams T, Towler C, Wang P, Williams SL, Zhang JH, LaMarche MJ. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Eff.
• the SHP2 inhibitor for use according to the present invention is a compound having a formula (I);
• Ri is selected from the group consisting of carboalkoxy, benzylcarboxamide, straight chained, branched or cyclic alkyl, C0(CH 2 ) 2 C0 2 H, C0CH 2 CH(0H)C0 2 H, C0(CH) 2 C0 2 H, CONH(C 6 H 4 )CI, CONH(C 6 H 4 )CH(CH 3 ) 2 , CONH(C 6 H 4 )(CI) 2 , C0(CH 2 ) 3 C0 2 H, CO(C 6 H 4 )OCH 3 , CO(C 5 H 8 ), CO(C 6 H 4 )CI, C0NHCH 2 C0 2 H, COCH 2 CH(CH 3 ) 2 , C0NHCH(CHCH 3 CH 2 CH 3 )(C0 2 H), CONH(C 6 H 4 )OCH 3 , CO(C 6 H 3 )(CI) 2 , COCH 2 (C 6 H 4 )CI, C0(CH 2 )
• R 2 is selected from the group consisting of H, and CH 3 ; and wherein R 3 is selected from the group consisting of (C 6 H 4 )CI, (C 6 H 4 )C0 2 H, (C 6 H 4 )CH 3 , (C 6 H 4 )(CI) 2 , (C 6 H 4 )(CF 3 ) 2 ,
• Rl is selected from the group consisting of COCH2CH2COOH and C0CH2CH(0H)C02H.
• R1 is selected from the group consisting of C0(CH)2C02H, CONH(C6H4)CH(CH3)2, C0(CH2)3C02H, C0NHCH2C02H, C0(CH2)2C02H, CONHCH(CHCH3CH3) (C02H) , C0C02H, C0NH(CH2)2C02H, and
• Rl is C0(CH2)2C02H, R2 is H, and R3 is (C6H4)CI.
• the SHP2 inhibitor for use according to the present invention is a compound having a formula (IV):
• Ri is selected from the group consisting of F; and wherein R2 is selected from the group consisting of COOCH3, and C0 2 " ⁇ N + H 2 (CH3)(CH2CHOH)4CH 2 OH).
• the SHP2 inhibitor for use according to the present invention is selected from the group consisting of:
• the SHP2 inhibitor is an inhibitor of SHP2 expression.
• inhibitor of expression refers to a natural or synthetic compound that has a biological effect to inhibit the expression of a gene.
• said inhibitor of gene expression is a siRNA, an antisense oligonucleotide or a ribozyme.
• anti- sense oligonucleotides including anti-sense RNA molecules and anti-sense DNA molecules, would act to directly block the translation of SHP2 mRNA by binding thereto and thus preventing protein translation or increasing mRNA degradation, thus decreasing the level of SHP2, and thus activity, in a cell.
• antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the mRNA transcript sequence encoding SHP2 can be synthesized, e.g., by conventional phosphodiester techniques.
• Methods for using antisense techniques for specifically inhibiting gene expression of genes whose sequence is known are well known in the art (e.g. see U.S. Pat. Nos. 6,566,135; 6,566,131; 6,365,354; 6,410,323; 6,107,091; 6,046,321; and 5,981,732).
• Small inhibitory RNAs siRNAs
• siRNAs can also function as inhibitors of expression for use in the present invention.
• SHP2 gene expression can be reduced by contacting a subject or cell with a small double stranded RNA (dsRNA), or a vector or construct causing the production of a small double stranded RNA, such that SHP2 gene expression is specifically inhibited (i.e. RNA interference or RNAi).
• dsRNA small double stranded RNA
• RNAi RNA interference or RNAi
• Antisense oligonucleotides, siRNAs, shRNAs and ribozymes of the invention may be delivered in vivo alone or in association with a vector.
• a "vector" is any vehicle capable of facilitating the transfer of the antisense oligonucleotide, siRNA, shRNA or ribozyme nucleic acid to the cells and typically cells expressing SHP2.
• the vector transports the nucleic acid to cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector.
• the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antisense oligonucleotide, siRNA, shRNA or ribozyme nucleic acid sequences.
• Viral vectors are a preferred type of vector and include, but are not limited to nucleic acid sequences from the following viruses: retrovirus, such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retro virus/lenti virus.
• retrovirus such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rous sarcoma virus
• adenovirus adeno-associated virus
• SV40-type viruses polyoma viruses
• Epstein-Barr viruses Epstein-Barr viruses
• papilloma viruses herpes virus
• the SHP2 inhibitor is embedded or conjugated to a nanoparticule, so that the SHP2 inhibitor would be preferentially deliver in myeloid cells (e.g. macrophages) that are able to phagocyte said nanoparticle.
• myeloid cells e.g. macrophages
• nanoparticle encompasses liposomes, polymer micelles, polymer-DNA complexes (polycomplexes), nanospheres, nanofibres, nanotubes, and nanocapsules. All these nanoparticles are known in the art. The surface of such nanoparticles is often modified by PEG brush (PEGylation, i.e. polyethylene glycol (PEG) is attached to the surface of the nanoparticles).
• the nanoparticle is a nanocapsule.
• the term “nanocapsules” means vesicular systems in which the drug is confined to a cavity surrounded by a uniquer polymer membrane.
• the nanoparticle is a nanosphere.
• the term “nanosphere” means a matrix system in which the drug is physically and uniformly dispersed.
• the nanoparticle is a liposome.
• liposome includes any structure composed of a lipid bilayer that enclose one or more volumes, wherein the volume can be an aqueous compartment.
• Liposome consist of one, two, three, four, five, six, seven, eight, nine, ten or more lipid bilayers.
• the term "lipid bilayer” includes, but is not limited to: phospholipid bilayer, bilayer consisting of nonionic surfactants.
• Liposomes consisting of a phospholipid bilayer can be composed of naturally- derived phospholipids with mixed lipid chains (like e.g. phosphatidylethanolamine), or of pure components like DOPE (dioleolylphosphatidyl-ethanolamine) but are not limited to these components.
• Liposomes include — but are not limited to- emulsions, foams, micelles, exosomes, vesicles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like.
• the term "liposome” also includes so called “stealth liposomes” which consist of water-soluble polymers (e.g. polyethyleneglycol, PEG) attached to the surface of conventional liposomes composed of a lipid mono- or bilayer that enclose a volume (e.g. so called PEGylated liposomes). Following liposome preparation, the liposomes may be sized to achieve a desired size range and relatively narrow distribution of liposome sizes.
• Methods of coupling inhibitors according to the present invention to liposomes generally involve either covalent cross linking between a liposomal lipid and an inhibitor.
• an inhibitor according to the present invention has been covalently derivatized with a hydrophobic anchor, such as fatty acids, is incorporated into a preformed lipid.
• the SHP2 inhibitor is administered to the subject in a therapeutically effective amount.
• a therapeutically effective amount is meant a sufficient amount of the active ingredient for treating or reducing the symptoms at reasonable benefit/risk ratio applicable to any medical treatment. It will be understood that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
• the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination with the active ingredients; and like factors well known in the medical arts.
• the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
• the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.
• a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, typically from 1 mg to about 100 mg of the active ingredient.
• An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
• the active ingredient of the present invention e.g. SHP2 inhibitor
• pharmaceutically acceptable excipients e.g. SHP2 inhibitor
• sustained-release matrices such as biodegradable polymers
• pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
• the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
• the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
• the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
• the active ingredients of the invention can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports.
• Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
• FIGURES are a diagrammatic representation of FIGURES.
• Figure 1 shows that obese diabetic mice treated by gavage with a SHP2 inhibitor (50mg / kg / day) have significant improvement in the glucose tolerance.
• SHP099 (6-(4-amino-4-methylpiperidin-l-yl)- 3-(2,3-dichlorophenyl)pyrazin-2-amine) that has recently been shown to be being highly specific, with good tolerance and oral bioavailability ( Garcia Fortanet J, Chen CH, Chen YN, Chen Z, Deng Z, Firestone B, Fekkes P, Fodor M, Fortin PD, Fridrich C, Grunenfelder D, Ho S, Kang ZB, Karki R, Kato M, Keen N, LaBonte LR, Larrow J, Lenoir F, Liu G, Liu S, Lombardo F, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Ramsey T, Sellers WR, Shultz Ml), Stams T, Towler C, Wang P, Williams SL, Zhang JH, La

Landscapes

• Health & Medical Sciences (AREA)
• Diabetes (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=64664217

Family Applications (1)

Country Status (4)

Cited By (28)

Families Citing this family (1)

Citations (14)

Family Cites Families (3)

• 2019
  • 2019-11-22 WO PCT/EP2019/082180 patent/WO2020104635A1/en not_active Ceased
  • 2019-11-22 US US17/295,600 patent/US20220000869A1/en not_active Abandoned
  • 2019-11-22 EP EP19805329.0A patent/EP3883574A1/en active Pending
  • 2019-11-22 JP JP2021526584A patent/JP7454573B2/ja active Active
• 2024
  • 2024-08-20 US US18/809,948 patent/US20250090529A1/en active Pending

Patent Citations (15)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events